A compound according to Formula: wherein: A 1, A 2, A 3, A 4, A 5, and A 6 are each independently N, CH, or CR 6; X is O or NR 8; R 1 and R 2 are each independently hydrogen, (C 1 -C 4)alkyl, or H 2 N(C 1 -C 4)alkyl-; or R 1 and R 2 taken together with the nitrogen atom to which they are attached represent a 4-11 membered monocyclic or fused, bridged, or spiro bicyclic saturated ring, optionally containing one or two additional heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by one, two, or three substituents independently selected from halogen, hydroxyl, oxo, -OCONR 8 R 9, -CO 2 R 8, -C CO 2 R 8, R 7, -OR 7, -NHR 8, -NR 7 R 8, - C R 7, -CONHR 8, -CONR 7 R 8, and -SO 2 R 7; each R 3 is independently selected from the group consisting of halogen, methyl, fluoromethyl, difluoromethyl, and trifluoromethyl; R 4 and R 5 are each independently hydrogen, (C 1 -C 4)alkyl, or (C 1 -C 4)alkoxy(C 2 -C 4)alkyl-; or R 4 and R 5 taken together with the nitrogen atom to which they are attached represent a 4-11 membered monocyclic or fused, bridged, or spiro bicyclic saturated ring, optionally containing one or two additional heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by one, two, or three substituents independently selected from halogen, hydroxyl, oxo, -OCONR 8 R 9, -CO 2 R 8, -C CO 2 R 8, -SO 2 (C 1 -C 4)alkyl, R 7, -OR 7, -NHR 8, -NR 7 R 8, -N(R 8)C R 9, -N(R 8)SO 2 R 9, -N(R 8)CONR 8 R 9, -N(R 8)CON(R 8)SO 2 R 9, -C R 7, -CONHR 8, -CONR 7 R 8, and -P R 8 R 9; each R 6 is independently selected from the group consisting of halogen, (C 1 -C 4)alkyl, halo(C 1 -C 4)alkyl, hydroxyl, and (C 1 -C 4)alkoxy; each R 7 is independently selected from the group consisting of (C 1 -C 6)alkyl, (C 2 -C 6)alkenyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, and (C 3 -C 6)cycloalkyl(C 1 -C 4)alkyl-, each of which is optionally substituted by one or two substituents independently selected from triazolyl, tetrazolyl, -CO 2 R 8, -CONR 8 R 9, -CON(R 8)CO 2 (C 1 -C 4)alkyl, hydroxyl, oxo, (C 1 -C 4)alkoxy, -OCONR 8 R 9, -OCON(R 8)C R 9, (C 1 -C 4)alkyl, HO(C 1 -C 4)alkyl-, -NR 8 R 9, -N R 8 R 9, -N(R 8)C R 9, -N(R 8)CO 2 (C 1 -C 4)alkyl, -N(R 8)CH 2 CO 2 R 9, -N(R 8)C ONR 8 R 9, -N(R 8)CON(R 8)C R 9, -N(R 8)CON(R 8)CO 2 (C 1 -C 4)alkyl, -N(R 8)SO 2 R 9, -N(R 8) CON(R 8)SO 2 R 9, -SO(C 1 -C 4)alkyl, -SO 2 (C 1 -C 4)alkyl, -SO 3 R 8, -SO 2 NR 8 R 9, - B 2, -P R 8 R 9, and -P (OR 8)(OR 9); each R 8 and R 9 is independently hydrogen, (C 1 -C 4)alkyl, or (C 3 -C 6)cycloalkyl; and n is 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof. A 1, A 2, A 3, A 4, A 5, and A 6 are each independently N, CH, or CR 6; X is O or NR 8; R 1 and R 2 are each independently hydrogen, (C 1 -C 4)alkyl, or H 2 N(C 1 -C 4)alkyl-; or R 1 and R 2 taken together with the nitrogen atom to which they are attached represent a 4-11 membered monocyclic or fused, bridged, or spiro bicyclic saturated ring, optionally containing one or two additional heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by one, two, or three substituents independently selected from halogen, hydroxyl, oxo, -OCONR 8 R 9, -CO 2 R 8, -C CO 2 R 8, R 7, -OR 7, -NHR 8, -NR 7 R 8, - C R 7, -CONHR 8, -CONR 7 R 8, and -SO 2 R 7; each R 3 is independently selected from the group consisting of halogen, methyl, fluoromethyl, difluoromethyl, and trifluoromethyl; R 4 and R 5 are each independently hydrogen, (C 1 -C 4)alkyl, or (C 1 -C 4)alkoxy(C 2 -C 4)alkyl-; or R 4 and R 5 taken together with the nitrogen atom to which they are attached represent a 4-11 membered monocyclic or fused, bridged, or spiro bicyclic saturated ring, optionally containing one or two additional heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by one, two, or three substituents independently selected from halogen, hydroxyl, oxo, -OCONR 8 R 9, -CO 2 R 8, -C CO 2 R 8, -SO 2 (C 1 -C 4)alkyl, R 7, -OR 7, -NHR 8, -NR 7 R 8, -N(R 8)C R 9, -N(R 8)SO 2 R 9, -N(R 8)CONR 8 R 9, -N(R 8)CON(R 8)SO 2 R 9, -C R 7, -CONHR 8, -CONR 7 R 8, and -P R 8 R 9; each R 6 is independently selected from the group consisting of halogen, (C 1 -C 4)alkyl, halo(C 1 -C 4)alkyl, hydroxyl, and (C 1 -C 4)alkoxy; each R 7 is independently selected from the group consisting of (C 1 -C 6)alkyl, (C 2 -C 6)alkenyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, and (C 3 -C 6)cycloalkyl(C 1 -C 4)alkyl-, each of which is optionally substituted by one or two substituents independently selected from triazolyl, tetrazolyl, -CO 2 R 8, -CONR 8 R 9, -CON(R 8)CO 2 (C 1 -C 4)alkyl, hydroxyl, oxo, (C 1 -C 4)alkoxy, -OCONR 8 R 9, -OCON(R 8)C R 9, (C 1 -C 4)alkyl, HO(C 1 -C 4)alkyl-, -NR 8 R 9, -N R 8 R 9, -N(R 8)C R 9, -N(R 8)CO 2 (C 1 -C 4)alkyl, -N(R 8)CH 2 CO 2 R 9, -N(R 8)C ONR 8 R 9, -N(R 8)CON(R 8)C R 9, -N(R 8)CON(R 8)CO 2 (C 1 -C 4)alkyl, -N(R 8)SO 2 R 9, -N(R 8) CON(R 8)SO 2 R 9, -SO(C 1 -C 4)alkyl, -SO 2 (C 1 -C 4)alkyl, -SO 3 R 8, -SO 2 NR 8 R 9, - B 2, -P R 8 R 9, and -P (OR 8)(OR 9); each R 8 and R 9 is independently hydrogen, (C 1 -C 4)alkyl, or (C 3 -C 6)cycloalkyl; and n is 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.